US 9006417

I'll verify the record against live sources before summarizing.

Let me pull the granted claim set directly.

I need the granted claim text specifically. Let me search for it directly.

Scope / confidence note first

Two things you should know before the summary:

1. I could not retrieve the granted claim text of US 9,006,417 from an authoritative source within this session. The claim language below is taken from the pre-grant publication US 2013/0303587 A1, which is the publication of the same application (13/807,288) that issued as 9,006,417. Published claims frequently change during prosecution, including in this family (the examiner allowed related claims on the basis of ranges narrowed to remove a double-patenting rejection — see the '069/'435 prosecution history discussed in IPR2019-00554 papers). Treat the claim wording below as a high-probability proxy, not as the verified issued text. Anything I mark "unverified" should be confirmed against the face of the patent.
2. I found no CAFC 2026 docket activity naming patent 9,006,417. I searched and did not surface any Federal Circuit appeal, order, or opinion in 2026 involving this number. I am not able to state that none exists — only that my searches produced none. Do not treat the absence as a clean bill of health.

I also deliberately did not reach for near-neighbours. Note that search results contain several lookalikes that are different documents — e.g. WO 9006417 (a 1990 PCT publication about tubing tongs), KR 9006417 B, and EP 1080689. These are unrelated and are not the patent you asked about.

Bibliographic summary — US 9,006,417 B2

Abstract (verbatim, as it appears for 9,006,417)

"The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP."

Note the deliberate wordplay: "non-liposomal" in the title maps onto "non-lamellar" / "non-bilayer" in the disclosure. The patent is claiming lipid nanoparticles whose internal structure is not a conventional bilayer vesicle.

Plain-language overview of the independent claims (unverified — see note above)

Claim 1 — Composition (the core genus claim).
A composition made up of a plurality of nucleic-acid-lipid particles, where each particle contains four things:

• (a) a nucleic acid payload;
• (b) a cationic lipid at ~50–85 mol% of total particle lipid;
• (c) a non-cationic lipid at ~13–49.5 mol%; and
• (d) an aggregation-inhibiting conjugated lipid (typically a PEG-lipid) at ~0.5–10 mol%;

and — the point of novelty — at least about 95% of the particles in the plurality have a non-lamellar morphology. In other words, the invention is a composition defined by a bulk physical-structure measurement, not just by a recipe. Support for measurement is given via cryo-TEM, X-ray diffraction, and DSC (no thermal transitions between 5–75 °C).

The commercial upshot, in the specification's own framing, is that these particles are serum-stable, smaller, less polydisperse, better at reaching extravascular sites and target cell populations, and better at silencing genes than earlier "2:40"-type SNALP formulations.

Claim 54 — Pharmaceutical composition. The claim-1 composition plus a pharmaceutically acceptable carrier. Purely a formulation claim.

Claim 55 — Method of introducing a therapeutic agent into a cell. Contact the cell with the claim-1 composition (i.e., in vitro / ex vivo delivery).

Claim 57 — Method of in vivo delivery of a therapeutic agent. Administer the claim-1 composition to a mammal.

Claim 60 — Method of treating a disease or disorder in a mammal. Administer a therapeutically effective amount of the claim-1 composition. This is the claim with the broadest therapeutic reach and therefore the one that matters commercially.

Dependent claims of note (same provenance caveat): the nucleic acid is an interfering RNA selected from siRNA, aiRNA, miRNA, Dicer-substrate dsRNA, shRNA, ssRNAi, and combinations (claim 2); the non-cationic lipid is a phospholipid/cholesterol mixture (claim 13); the conjugate is a PEG-lipid, e.g. PEG-DAG, PEG-DAA, PEG-phospholipid or PEG-ceramide (claims 17, 21); the RNA is fully encapsulated (claim 27); and a "1:57"-style narrowing to ~52–62 mol% cationic lipid, ~36–47 mol% non-cationic, ~1–2 mol% PEG-lipid (claims 30–32) — the so-called 1:57 SNALP formulation that recurs throughout the family.

Family context (this matters for claim-scope questions)

9,006,417 sits in a dense Arbutus/Protiva family. Documents I can confirm from the record:

• US 9,404,127 B2 — expressly stated to be a continuation of application 13/807,288 (i.e., of the '417 application). Per a Korean IP- analysis table indexing the family, claims 1–20 of the '127 patent drew a non-statutory double-patenting objection over US 9,006,417 and were allowed only after a terminal disclaimer. If accurate, that is a secondary-source datum, not something I verified on the face of either patent.
• US 9,364,435 B2, US 9,518,272 B2, and US 2017/0260523 A1 (from app. 15/342,020) are further members carrying the same title.
• The same specification text underlies US 11,718,852 B2 and later members.

Litigation / docket status

Confirmed from the patent record itself: Google Patents links two US district-court cases to this family:

• D.N.J. 3:23-cv-04200
• S.D.N.Y. 1:22-cv-02229

Confirmed from Arbutus's own SEC filings and law-firm analyses: the S.D.N.Y. action is Acuitas Therapeutics v. Arbutus Biopharma / Genevant Sciences (filed 2022-03-18), a declaratory-judgment action seeking a ruling that Comirnaty does not infringe, and that the asserted Arbutus patents are invalid. US 9,006,417 is one of the nine patents named in that complaint. The D.N.J. matter is a later Acuitas DJ filing against a similar patent list (which includes 9,006,417). Arbutus/Genevant moved to dismiss the S.D.N.Y. action for lack of subject-matter jurisdiction (case-or-controversy).

Separately, in Arbutus/Genevant v. Moderna (D. Del., filed 2022-02-28, over Spikevax), the patents asserted were 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; and 11,141,378 — 9,006,417 was not among them. That case went to a February 2024 claim-construction ruling and a trial date that was moved to September 2025.

There is also an IPR (IPR2019-00554) in this technology space involving what the papers call the '127 patent (i.e., US 9,404,127), concerning whether certain SNALP particles inherently exhibit the >95% non-lamellar morphology. That is a challenge to a sibling patent, not to 9,006,417 — but it is directly relevant if you care about the validity of the "at least about 95% non-lamellar morphology" limitation, because that limitation is the shared point of novelty.

CAFC 2026: nothing found. See the caveat in the scope note.

Where I am uncertain

• Granted claim text of 9,006,417: not independently verified. The mol% figures (50–85 / 13–49.5 / 0.5–10) and the "at least about 95%" limitation are quoted from US 2013/0303587 A1. Confirm against the issued patent before relying on them.
• Independence of claims 54, 55, 57, 60: these are independent on the face of the publication, but a claim could have been cancelled or amended to depend on another claim during prosecution.
• Terminal disclaimer over '417 by the '127 patent: secondary source only (a Korean patent-analysis summary). Plausible and consistent with the IPR record, but unverified.
• Assignee chain: Google Patents records a 2013-05-21 assignment to Protiva and a 2018-02-20 merger-based assignment to Arbutus Biopharma Corporation. Modern chain-of-title for a patent with this much litigation behind it may involve further licenses (notably the Genevant exclusive licence) that are not reflected in the front page.
• Expiration 2031-06-30 is Google's automated estimate keyed to the PCT filing date; it ignores any terminal disclaimer, PTA/PTE, or maintenance-fee lapse.

I'll research litigation involving US patent 9006417 across multiple sources.

The generic searches are noisy. The patent itself lists litigation. Let me verify those specific cases.

Let me verify whether US 9006417 itself was asserted in those cases and search for other cases.

Litigation Involving U.S. Patent 9,006,417

Caveat on methodology: I was able to retrieve Google Patents' family-level litigation flags, PACER-derived docket summaries, and law-firm/blog case reports, but I could not complete a direct PACER/CAFC docket pull for every related case before hitting my search limit. Where I could not confirm the '417 patent on the face of a complaint, I say so explicitly rather than inferring.

The patent itself (US 9,006,417 B2, "Non-liposomal systems for nucleic acid delivery," Arbutus Biopharma Corp., application 13/807,288, priority 2010‑06‑30, granted 2015‑04‑14) is flagged in Google Patents as having family litigation in two U.S. district courts. I independently verified that the '417 patent was expressly named in both of those actions:

1. Acuitas Therapeutics, Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp.

• Court / jurisdiction: U.S. District Court, Southern District of New York
• Case number: 1:22-cv-02229 (initially assigned to Judge Edgardo Ramos; later Judge Mary Kay Vyskocil, docketed as 1:22-cv-02229-MKV)
• Filed: March 18, 2022
• Nature: Declaratory judgment — non-infringement and invalidity of the Arbutus patents, including U.S. Patent No. 9,006,417 (listed as Exhibit D to the Amended Complaint), in connection with the Pfizer/BioNTech COVID-19 vaccine COMIRNATY® and Acuitas's lipid nanoparticle (LNP) technology
• Outcome / status: Closed. Acuitas filed a Notice of Voluntary Dismissal Without Prejudice on August 4, 2023; the case was terminated August 7, 2023. This dismissal coincided with Acuitas refiling its declaratory judgment action in New Jersey (Case 2 below).

2. Acuitas Therapeutics, Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp.

• Court / jurisdiction: U.S. District Court, District of New Jersey
• Case number: 3:23-cv-04200 (3:23-cv-04200-ZNQ-TJB — Judge Zahid N. Quraishi)
• Filed: August 4, 2023
• Nature: Declaratory judgment of non-infringement and invalidity as to ten Arbutus patents, expressly including U.S. Patent No. 9,006,417, along with 9,364,435; 8,058,069; 8,492,359; 8,822,668; 9,504,651; 9,518,272; 11,141,378; 11,298,320; and 11,318,098
• Outcome / status: Closed May 20, 2024. Judge Quraishi granted Defendants' Motion to Dismiss (ECF No. 13) and dismissed the Complaint without prejudice — an order based on the accompanying Opinion. Recorded basis of termination: dismissed without prejudice.

Related Actions in Which '417 Was Not Confirmed on the Face of the Pleading

These arise from the same Arbutus/Genevant COVID-19 LNP enforcement campaign, and the '417 patent was named in Arbutus's and Genevant's pre-suit § 287(a) notice letters, but I could not confirm that '417 was among the patents actually asserted in the complaints:

• Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Pfizer Inc. and BioNTech SE — D.N.J., Case No. 3:23-cv-01876, filed April 4, 2023. Reported to assert five of the ten Arbutus patents that Acuitas later challenged in the D.N.J. declaratory judgment action. I could not verify from the sources retrieved whether 9,006,417 was one of the five asserted. (Google Patents lists the Nov. 23, 2020 § 287(a) notice as naming, among others, 9,006,417.)
• Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Moderna, Inc. / ModernaTX, Inc. — filed February 28, 2022 (District of Delaware), reported to assert six patents overlapping with those at issue in the S.D.N.Y. action (Case 1). Whether 9,006,417 was among the six is unconfirmed.

Negative Findings

• No inter partes review, post-grant review, or CBM proceeding against U.S. Patent 9,006,417 was identified in my searches. (Note: the IPR2019‑00554 filed by Moderna Therapeutics that surfaces in related Arbutus-family materials concerns a different patent in the family, not the '417 patent — do not conflate.)
• No CAFC appeal of the '417 patent was identified; the S.D.N.Y. case ended by voluntary dismissal and the D.N.J. case by dismissal on jurisdictional grounds, so no merits appeal was available.
• No ITC Section 337 investigation involving the '417 patent was identified.
• The two pre-2012 Acuitas/Arbutus litigations over LNP inventorship referenced in Acuitas's D.N.J. complaint predate the '417 patent's April 14, 2015 grant, so the '417 patent could not have been asserted there.

Bottom line

U.S. Patent 9,006,417 has been at issue in two confirmed U.S. district court cases, both brought by Acuitas Therapeutics as declaratory-judgment plaintiff against Genevant Sciences GmbH and Arbutus Biopharma Corp. (S.D.N.Y. 1:22-cv-02229; D.N.J. 3:23-cv-04200), and both are now closed — the first by voluntary dismissal without prejudice, the second by dismissal without prejudice on a motion to dismiss. It was also named in pre-suit notice letters to Pfizer/BioNTech and possibly Moderna.

If you need the precise asserted-patent list from the Pfizer/BioNTech (3:23-cv-01876) and Moderna complaints, or the full docket sheets, I can run targeted PACER/CourtListener pulls for those case numbers on request.

I'll verify the PTAB record with targeted searches before writing the analysis.

Let me run additional targeted checks for any proceeding specifically naming the '417 patent.

Let me check the Vaccine Patent PTAB Tracker and confirm the family relationships of the similarly-titled patents.

Proceedings overview

Total AIA trial proceedings on U.S. Patent 9,006,417: 0. The canonical structured list ("PTAB proceedings on file," sourced from the USPTO Open Data Portal) is empty, and my independent verification (Google Patents family-level litigation/PTAB flags, the Big Molecule Watch Vaccine Patent PTAB Tracker, Arbutus's own SEC filings and proxy disclosures, and targeted searches on the patent number and its title) surfaced no IPR, PGR, or CBM petition ever filed against the '417 patent — institution denied, settled, or otherwise. Because the '417 patent has an effective filing date of 2010‑06‑30 (well before 2013‑03‑16), PGR was never legally available, and CBM (a financial-services-patent vehicle, now sunset) is inapplicable — so IPR is the only AIA trial vehicle that ever could have reached this patent, and none was filed.

Bottom-line defensive posture: the '417 patent is not "hardened" by surviving IPRs — it is simply untested. All of its claims stand as issued, and no petitioner is burdened by § 315(e) estoppel. That cuts both ways for a defendant: there is no favorable FWD to lean on, but there is also no adverse claim-cancellation record and no estoppel bar. Plan for a first-challenge IPR rather than a "me-too" follow-on, and expect the parallel-litigation and "settled expectations" discretionary-denial headwinds that now dominate 2025–2026 institution practice for a patent that has been in force since 2015‑04‑14 (see Strategic summary).

Proceedings against US 9,006,417

None

There are no proceedings to report. I will not manufacture a proceeding number, panel, or claim-level outcome to fill this section. What I can report with confidence is the absence and the surrounding record that explains it:

• Google Patents' page for US9006417B2 carries litigation flags (S.D.N.Y. 1:22‑cv‑02229 and D.N.J. 3:23‑cv‑04200) but no PTAB/IPR flag.
• The USPTO ODP ingest returns no AIA trial proceedings for this patent.
• The '417 patent was named in Arbutus/Genevant's pre-suit § 287(a) notice letters (Nov. 23, 2020, per Google Patents) and in Acuitas's declaratory-judgment complaints, yet no petitioner — Acuitas, Pfizer/BioNTech, Moderna, or Moderna's prior IPR counsel — ever filed an IPR against it.

Why the well has stayed dry (my analysis, not a documented holding): Acuitas did challenge the '417 patent — but as an affirmative declaratory-judgment plaintiff in district court (S.D.N.Y. 2022‑03‑18; refiled D.N.J. 2023‑08‑04), not at the PTAB. That choice has a statutory consequence worth flagging for anyone mapping the estoppel landscape: 35 U.S.C. § 315(a)(1) bars institution of an IPR if the petitioner (or its RPI) filed a civil action challenging validity of a claim of that patent before the petition date. Acuitas's DJ count as to the '417 patent therefore forecloses an Acuitas IPR filed after 2022‑03‑18. Similarly, Moderna's 2018–2019 IPR program targeted the '127, '435, and '069 patents, not the '417 — likely because Moderna's articulated dispute was framed around those three.

Related PTAB proceedings on sister patents — context only, NOT proceedings on the '417 patent

These matter to a '417 defendant because they supply the winning prior-art theory and the patent owner's own admissions, but the reader must not treat these as decisions about 9,006,417. All three were brought by Moderna Therapeutics, Inc. against Arbutus/Protiva patents.

IPR2018-00680 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp. (U.S. 9,404,127)

• Type: Inter Partes Review
• Filed: 2018‑02‑21
• Status (as reported): All challenged claims held unpatentable; affirmed on appeal.
• Judge panel: not retrieved with confidence — omitted rather than guessed.
• Petition grounds: § 102 anticipation — the asserted art was Arbutus's own earlier U.S. Patent No. 8,058,069 (the "'069 patent"), including material incorporated by reference into it.
• Institution decision: instituted 2018‑09‑12 (per the Federal Circuit's recitation of the procedural history).
• Final Written Decision: 2019‑09‑10 — all 22 claims of the '127 patent held invalid as anticipated. Claim-level: independent claim 1 (including the "at least about 95% ... non‑lamellar morphology" ["Morphology Limitation"] element) and dependent claims 3 and 8–12 were all found anticipated.
• Settlement / termination: none — decided on the merits.
• Appeal: Yes. Affirmed by the Federal Circuit on 2023‑04‑11 in a precedential decision (Arbutus Biopharma Corp. v. ModernaTX, Inc.). The court held the Morphology Limitation was inherently disclosed by the '069 patent, and that because "Arbutus chose to incorporate several references into both the prior art patent and '127 patent, that material became incorporated into the host document." See IPWatchdog coverage and Stones Law summary.
• Defensive value (to '417): High, but indirect. The '127 patent is titled identically to the '417 patent ("Non-liposomal systems for nucleic acid delivery") and shares the non-lamellar/SNALP subject matter. A defendant should harvest the incorporation-by-reference anticipation framework and the inherency holding from this FWD/opinion — they are effectively a roadmap for attacking any Arbutus LNP patent claiming the non-lamellar morphology, provided the same priority/§ 102 relationships hold.

IPR2018-00739 — Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc. (U.S. 9,364,435)

• Type: Inter Partes Review
• Filed: 2018‑03‑05 (Petition, Paper 2)
• Status (as reported): Mixed — certain claims invalidated, others upheld; the sole independent claim was invalidated.
• Judge panel: not retrieved — omitted.
• Petition grounds: § 102/§ 103 challenge to the '435 patent. (Arbutus's Patent Owner Response at 18 in this proceeding contains the unpredictability admission later used against it: "The effects of making changes to the proportion of other components in the lipid particle would be unpredictable.")
• Final Written Decision: 2019‑09‑11 (Paper 51).
• Appeal: Fed. Cir. Appeal No. 2020‑1184 (ModernaTX, Inc. v. Arbutus Biopharma Corp.); reported disposition by summary affirmance (Rule 36). Confidence: medium on the precise disposition; the docket number is documented in the D. Del. exhibit index.

IPR2019-00554 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp. (U.S. 8,058,069)

• Type: Inter Partes Review
• Filed: 2019‑01‑09
• Status (as reported): Patent owner prevailed — claims sustained; affirmed on appeal.
• Judge panel: not retrieved — omitted.
• Petition grounds: § 102/§ 103 against the '069 patent (the very reference Moderna had used to kill the '127 patent).
• Final Written Decision: 2020‑07‑23 (Paper 40) — Moderna "not shown by a preponderance of the evidence that claims 1‑22 of the patent are unpatentable." All 22 claims upheld.
• Appeal: Fed. Cir. Appeal No. 2020‑2329 — affirmed 2021‑12‑01; mandate issued 2022‑01‑10.
• Defensive value (to '417): Mixed / cautionary. The '069 patent is the linchpin of Arbutus's LNP portfolio and it survived IPR and appeal. If a '417 theory depends on the '069 patent as prior art, note the asymmetry: the '069 patent is invalidating art against the '127 patent but is itself valid. Also relevant: the '069 patent's challenged U.S. claims were sustained — and IPR2019‑00554 is frequently mis-cited as a '417 proceeding; it is not one.

Reference links: Unified Patents PTAB case page for IPR2019-00554; Big Molecule Watch Vaccine Patent PTAB Tracker; D. Del. 1:22-cv-00252 exhibit index (IPR papers).

Identifier-confusion warnings (read before you search)

Three traps will produce false "the '417 patent was invalidated" conclusions:

1. U.S. 9,404,127 (the "'127 patent") shares the exact title of the '417 patent — "Non-liposomal systems for nucleic acid delivery." The '127 patent is the one all 22 claims of which were invalidated (IPR2018‑00680; CAFC affirmed 2023‑04‑11). The '417 patent's claims were not at issue in that IPR.
2. One Arbutus filing excerpt renders the '417 number as "9,064,417." Per my operating rules I read patent identifiers literally, so I flag this as an apparent typographical/OCR variant of "9,006,417" rather than auto-correcting it. Do not let this variant number propagate into your invalidity contentions or IPR papers.
3. Secondary sources (including a Korean BIO-IP issue paper and the IPWatchdog headline) describe the invalidated patent as "US 9404127" and attach the '417 title to it. Same conflation — the invalidated patent is 9,404,127.

Strategic summary

Claim status of 9,006,417. Every claim of the '417 patent is UNTESTED at the PTAB — none canceled, none sustained through an AIA trial, none amended. The only adverse claim-level record in this family is against the sister '127 patent, all of whose claims (including the non-lamellar "Morphology Limitation" in claim 1 and dependents 3, 8–12) were canceled as anticipated by the '069 patent. Whether that inherency/incorporation-by-reference theory reaches the '417 patent turns on a § 102 priority question I cannot answer from the record retrieved: the '417 patent has an effective filing date of 2010‑06‑30 (application 13/807,288, filed 2011‑06‑30), whereas the '069 patent was filed 2009‑04‑15 with priority to a 2008‑04‑15 provisional. That temporal relationship is potentially favorable to a challenger — the '069 patent may itself be § 102 prior art to the '417 patent — but it must be confirmed against the '417 specification's priority claims and any benefit claims. Do not assume it; verify it. Flagging this as a hypothesis, not a finding.

Estoppel landscape. Because no IPR was ever instituted on the '417 patent, § 315(e)(2) estoppel is zero — no petitioner or privy is estopped from raising any ground in district court or before the Office. Conversely, no § 315(b) one-year bar is established on this record: the litigation summary could not confirm that the '417 patent was actually asserted in Arbutus/Genevant's affirmative complaints against Pfizer/BioNTech (D.N.J. 3:23‑cv‑01876, filed 2023‑04‑04) or Moderna (D. Del., filed 2022‑02‑28). It was named in § 287(a) notice letters, and pre-suit notice letters do not trigger § 315(b) — only service of a complaint alleging infringement does. So a defendant not yet served on the '417 patent likely still sits outside the bar, and any and all prior-art grounds remain available. Confirm service date before relying on this.

Pattern signals. (a) Moderna was the only serial petitioner against Arbutus's LNP patents and filed three IPRs (2018‑00680, 2018‑00739, 2019‑00554) — none on the '417 patent. (b) Arbutus defends the portfolio aggressively in district court but has never had to defend the '417 patent at the PTAB; its appellate track record is split (lost badly on '127, won on '069). (c) No defensive aggregator (e.g., Unified Patents) appears anywhere in the '417 chain — Unified's portal indexes Arbutus patents (e.g., US 9,504,651) but shows no '417 challenge.

The 2026 timing problem is the real strategic story. A first-challenge IPR on a patent that issued 2015‑04‑14 — now ~11 years in force — lands squarely in the new discretionary-denial regime. Public reporting for 2025–2026 shows institution rates collapsing, a record 607 procedural denials in 2025, and the "settled expectations" doctrine (patents in force ~6+ years) appearing as a basis in roughly 60% of discretionary denials. The October 2025 NPRM would go further, requiring a mandatory stipulation abandoning all § 102/103 defenses in every other forum and mandatory denial where a claim was previously upheld by the USPTO, ITC, or a court. Net: the '417 patent's age is now a defensive asset for Arbutus and a procedural hazard for you. Budget for a Discretionary Denial Brief, a Petition for POPR-cycle briefing, and a materially elevated risk of denial without merits review.

Recommended next steps

1. No FWD to cite. There is no claim-invalidated Final Written Decision on the '417 patent to quote — say so plainly in any client memo. Do not cite IPR2018‑00680's all-claims invalidation as if it applied to the '417 patent; it applied to U.S. 9,404,127.
2. Confirm priority and the § 102 status of the '069 patent against the '417 patent. Pull the '417 patent's full specification and any benefit/priority claims, and the '069 patent's filing chain. If the '069 patent is § 102(b) art to the '417 patent, the IPR2018‑00680 theory (anticipation, including by material incorporated by reference) transfers directly. This is your highest-value pre-filing diligence item.
3. Verify the § 315(b) clock. Determine whether you (or a privy) have been served with a complaint alleging infringement of the '417 patent in the Moderna (D. Del.) or Pfizer/BioNTech (D.N.J. 3:23‑cv‑01876) actions, and the exact service date. If unserved, the bar has not started; if served, calendar it immediately.
4. Screen for § 315(a)(1) and § 325(a)(1) self-inflicted bars. If you previously filed a DJ or affirmative validity challenge on the '417 patent — as Acuitas did — your IPR path may already be closed.
5. If you file, file strong and file once. No estoppel exists yet, so there is no "second bite" penalty from a prior petitioner — but the new regime's follow-on-petition and mandatory-stipulation proposals make a weak first petition expensive. Note also that the extraordinary 2025–2026 rise in ex parte reexamination requests (a record 726 in 2025) reflects defendants routing around PTAB discretionary denials; consider ex parte reexam as a hedge, weighing its narrower estoppel and lack of a § 315(b) clock against the loss of PTAB discovery and claim-construction procedure.
6. Watch the parallel district court. Acuitas's D.N.J. DJ action (3:23‑cv‑04200) was dismissed without prejudice on 2024‑05‑20; the Moderna and Pfizer/BioNTech affirmative cases remain the live validity venues for this family. Any district-court validity ruling on the '417 patent would be a candidate basis for denial under the proposed rules.

Confidence statement: I am confident in the central finding (zero AIA trials on 9,006,417) based on the ODP ingest, Google Patents, the Vaccine Patent PTAB Tracker, and Arbutus's own filings. I am less confident on the precise Federal Circuit dispositions of Appeal Nos. 2020‑1184 and 2020‑2329, and I did not recover APJ panel names for any related proceeding — those fields are left blank above rather than guessed.

I'll research the assignment record for US 9,006,417 before writing anything. Let me pull from multiple angles.

Good context on the corporate chain. Now let me try to pin down actual reel/frame records and correspondents.

Preliminary: source limitation up front

I must flag a hard limitation before anything else, because it changes how you should read this report.

I could not open the USPTO Assignment Center record for 9,006,417. My searches returned Google Patents' legal-events panel (the same star-schema events already cited in the earlier sections of this analysis), SEC exhibits, and PTAB papers — but no reel/frame numbers and no correspondent-of-record data. I therefore cannot report reel/frame, execution dates as recorded, or the recording attorney for either assignment. I am not going to invent them.

What I can report is a content-and-date reconstruction of the chain from:

• Google Patents legal events for 9,006,417 (already quoted in the prior sections, so I won't re-quote the star schema);
• Arbutus's own SEC filings and investor releases (10-K, 424B5, subsidiary lists);
• A PTAB mandatory-notices paper that states the Protiva→Arbutus amalgamation date.

Everything below is tagged accordingly. Any NPE signal that depends on reel/frame or correspondent is marked unclear and the reason given — not guessed.

Inventors

Note on "employer." The inventors are not named as applicants; the applicant of record is Protiva Biotherapeutics, Inc., and the inventors are recorded as assignors to Protiva (Google Patents legal event, 2013-05-21: "ASSIGNMENT OF ASSIGNORS INTEREST … Assignors: JEFFS, LLOYD B., YAWORSKI, ED, PALMER, LORNE R."). An assignment-of-inventors'-interest to the applicant is consistent with employee/contractor invention-assignment obligations, which is the basis for listing Protiva as employer. I did not retrieve the actual assignment instrument, so this is inference from the recording type, not from the document text.

Unusual-pattern check — could not be performed. The requested test (e.g. all inventors departing the original assignee within 12 months of filing, a classic precursor to a portfolio fire-sale) requires employment-history data I could not retrieve. I found no evidence of inventor departures in the sources returned, and I am not reporting the absence as a finding — it is simply unmeasured. Do not read "no finding" as "clean."

Original assignee

Protiva Biotherapeutics, Inc. — Burnaby, British Columbia, Canada. Named on the face of the issued patent (Google Patents front page: "Original Assignee: Protiva Biotherapeutics Inc").

• Primary line of business: preclinical/clinical-stage biotech developing nucleic-acid (RNAi) therapeutics and, critically, the lipid-nanoparticle delivery technology (SNALP) recited in this patent. Not a commercial manufacturer.
• Did they ship a product embodying the claims? No — not Protiva itself. Protiva never commercialized a product. Its LNP delivery platform was licensed out, and the technology family is the one that later underpinned Alnylam's Onpattro and, per the litigation record, the LNP systems used in the COVID-19 mRNA vaccines. The value in this patent is licensing/royalty value, not product revenue — which matters for the NPE analysis below (a licensing-revenue model is not, by itself, an NPE pattern when the owner is an operating drug developer).
• Current status: Not operating as an independent entity. Two-step history, both confirmed:
  1. June 1, 2008 — Tekmira Pharmaceuticals Corporation completed a business combination acquiring all outstanding equity of Protiva; Protiva became a wholly-owned subsidiary of Tekmira (Arbutus investor release, "Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination," Jun 1 2008; Arbutus subsidiary list confirms Protiva became a wholly-owned subsidiary May 30, 2008, BC, Canada).
  2. January 2018 — Protiva was amalgamated into Arbutus Biopharma Corporation (PTAB paper, Patent Owner's Updated Mandatory Notices, filed 2018-07-19: "Protiva Biotherapeutics, Inc. was amalgamated into Arbutus Biopharma Corporation in January 2018"). This matches Google Patents' recorded event "2018-02-20 — Assigned to ARBUTUS BIOPHARMA CORPORATION — MERGER — Assignors: PROTIVA BIOTHERAPEUTICS INC."

Source-quality caution on the 2008 deal. Merger/Mergr and Crunchbase describe the 2008 transaction as "Arbutus Biopharma acquired Protiva Biotherapeutics." That is a retroactive relabeling — the acquirer in 2008 was Tekmira, which only later took the Arbutus name (2015). Treat those aggregator entries as name-artifacts, not as evidence of a 2008 Arbutus transaction.

Assignment timeline

Read this with the caveat above: the only assignment records I could confirm are the two post-filing reassignment events surfaced by Google Patents. Reel/frame numbers and correspondents are not available to me. I am listing execution/recording dates as the record shows them, and marking reel/frame as not retrieved rather than inventing a number.

1. (execution date not retrieved) / recorded 2013-05-21 — Reel/frame: NOT RETRIEVED

• Conveyance: Assignment of assignors' interest (inventor → applicant).
• Assignor: Lloyd B. Jeffs; Ed Yaworski; Lorne R. Palmer (individually).
• Assignee: Protiva Biotherapeutics, Inc.
• Correspondent: not retrieved — I will not name a firm here.
• Context: Routine inventor-to-employer assignment perfecting title in the applicant; standard, not a fire-sale or transfer-to-asserter.

2. (executed January 2018 per PTAB paper) / recorded 2018-02-20 — Reel/frame: NOT RETRIEVED

• Conveyance: Merger (Google Patents event type). Substance: amalgamation of Protiva Biotherapeutics, Inc. into its parent, Arbutus Biopharma Corporation.
• Assignor: Protiva Biotherapeutics, Inc.
• Assignee: Arbutus Biopharma Corporation.
• Correspondent: not retrieved.
• Context: Internal corporate reorganization — a subsidiary collapsing into its parent. Not an arm's-length sale; no consideration flowing to a third party; ownership of the patent never left the Tekmira/Arbutus corporate group.

Nothing else is recorded in the sources I retrieved. In particular: no security agreement, no release, no change-of-name record, no license record, and no transfer to any third-party or LLC. I checked for security interests specifically because a recorded security agreement in an Arbutus/Tekmira chain would be an important ownership caveat — I found none recorded, and I found none referenced in the litigation or SEC materials returned.

One non-recorded ownership fact you should carry alongside the above, because it is not on the Assignment Center and would be missed by a pure reel/frame reconstruction: Genevant Sciences holds an exclusive licence to the LNP patents and is named, with Arbutus, as a real party in interest in the family's PTAB notices ("Patent Owner identifies Arbutus Biopharma Corporation (fka 'Tekmira') and Genevant Sciences, Inc. as the real parties-in-interest"). A licence is not an assignment and does not appear as a link in the recorded chain — but it is where the assertion capacity in this family actually sits.

Timeline diagram

timeline
    title Ownership of US 9006417
    2010 : Provisional priority filed by Protiva
    2011 : PCT and US national phase filed
    2013 : Inventor assignment to Protiva recorded
         : US application published
    2015 : Patent granted to Protiva
         : Tekmira renamed Arbutus Biopharma
    2018 : Protiva amalgamated into Arbutus
    2022 : Named in Acuitas DJ suit New York
    2023 : Named in Acuitas DJ suit New Jersey

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The entire recorded chain is two entities: Protiva Biotherapeutics, Inc. → Arbutus Biopharma Corporation. Both are identifiable Canadian/US biopharmaceutical operating companies with physical addresses (Burnaby, BC; Warminster, PA), SEC reporting obligations, and disclosed drug pipelines. There is no "IP / Holdings / Licensing / Ventures" LLC, no Delaware or Texas single-member LLC, no registered-agent service address anywhere in the chain I could retrieve. This is the single most important negative in this report.

2. Known asserter in the chain — NOT PRESENT.
Neither current nor prior recorded assignee matches the supplied NPE list (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Arbutus Biopharma Corporation (NASDAQ: ABUS) is an operating hepatitis-B drug developer; it is a plaintiff in LNP patent litigation, but as an operating company asserting against actual market competitors, not as a monetization vehicle. Caveat I want on the record: the family's enforcement is run jointly with Genevant Sciences, a licensing-oriented joint venture (Arbutus/Roivant). Genevant is a genuine licensing vehicle — but it is a licensee and co-plaintiff, not an assignee, so it does not appear in the reel/frame chain and does not convert this into an NPE chain.

3. Repeat correspondent across the chain — UNCLEAR (undetermined, not absent).
I could not retrieve the correspondent of record for either recording, so I cannot test whether a single attorney/firm handled both links. I will not name a firm on speculation. This is the one signal most likely to change the picture if you pull the records, and it is the reason to do the manual pull described in the Verdict.

4. Cascading transfers — NOT PRESENT.
Only two recorded transfers across ~5 years (2013 and 2018), both corporate-entity events (inventor assignment; parent-subsidiary amalgamation). No chained LLC hops, no clustering inside 24 months, no shared-correspondent-address pattern detectable.

5. Pre-litigation transfer — NOT PRESENT.
Last recorded transfer 2018-02-20. First suit naming the '417 patent: S.D.N.Y. 1:22-cv-02229, filed 2022-03-18 — a ~4-year gap. There is no transfer inside the 6-month window before that filing. (Note the direction of that suit too: it was brought by Acuitas as declaratory-judgment plaintiff against Arbutus/Genevant, i.e. the '417 patent was a target, not an asserted weapon, in that case.)

6. Bankruptcy fire-sale — NOT PRESENT.
Neither Protiva nor Tekmira/Arbutus entered Chapter 7/11, and no bankruptcy sale of this patent is recorded or referenced in the materials returned. The 2018 event was a solvent internal amalgamation, not a distressed disposal. (Contrast the Kodak/Nortel polar cases — inapplicable here.)

7. Privateering — NOT PRESENT as to the recorded chain; UNCLEAR as to enforcement posture.
An operating company transferring to an NPE that sues on its behalf would show up as a recorded assignment to an assertion entity. It does not. The record shows Arbutus retaining ownership and asserting (with its JV licensee Genevant) against Pfizer/BioNTech and Moderna. That is ordinary operating-company enforcement, not privateering. I flag it as unclear only because the Genevant JV structure means the assertion-side entity is a licensing vehicle rather than the practising company itself.

8. Defensive aggregator — NOT PRESENT.
No RPX, AST, LOT, Unified, or OIN link anywhere. The patent has not been neutralized; the opposite — it is in active litigation as a challenged patent.

Verdict

Operating-company assertion.

The recorded chain contains zero NPE signals that survive the evidence threshold: two links only — inventors → Protiva Biotherapeutics, Inc. (recorded 2013-05-21), then Protiva → Arbutus Biopharma Corporation by merger (executed January 2018, recorded 2018-02-20). The current assignee is a NASDAQ-listed operating drug developer, the 2018 transfer was a solvent parent-subsidiary amalgamation, and the patent's litigation posture is as a defensive target in Acuitas's declaratory-judgment suits rather than as a shell-vehicled assertion weapon. I would add one honest qualifier: this verdict is driven by entity identity and deal character, not by the reel/frame and correspondent analysis you asked for, which I could not obtain.

To verify and close the two open items, pull the records directly:

• USPTO Patent Assignment Search — https://assignment.uspto.gov/patent/index.html (search property 9006417), and the Assignment Center at https://assignmentcenter.uspto.gov/
• Specifically capture: reel/frame for the 2013-05-21 inventor assignment and for the 2018-02-20 merger, the execution dates, and the correspondent of record on each — that last field is the only input that could move signal #3 off "unclear."
• Cross-check the 2018 recording against the Arbutus 10-K subsidiary schedule and the PTAB mandatory-notices paper (Protiva amalgamated into Arbutus January 2018) to confirm the merger link is the sole post-issuance transfer.

One correction to the earlier sections, for the record. The prior "Family context" section inferred the Protiva→Arbutus step from Google Patents' summary alone. The PTAB mandatory-notices paper ("Protiva Biotherapeutics, Inc. was amalgamated into Arbutus Biopharma Corporation in January 2018") is a stronger, primary-adjacent source for that date and should be preferred over the Google legal-event date of 2018-02-20, which is a recording date, not an execution date. No contradiction — a refinement.

I'll research the cited prior art on the face of US 9,006,417. Let me pull the patent's own reference lists and the USPTO record.

Let me pull the actual "References Cited" list from US 9,006,417 and the key IPR/prior-art details.

I have good leads. Let me retrieve the complete cited-reference lists (US, foreign, and non-patent) from the '417 face and the WO 2012/000104 family member.

Scope, method, and one important correction

Method. I could not run a direct PatentCenter/PatentScope query in-session; I worked from the public record (Google Patents, Justia, PTAB filings, and a foreign patent-office family table). I searched the literal number 9,006,417 / US9006417B2 and ignored lookalikes (WO 9006417 — tubing tongs; KR 9006417 B; EP 1080689; the German psychological-test code "[9006417]"). None of those are the patent you asked about.

Correction to the earlier "Litigation summary" section. That section flagged IPR2019‑00554 as the proceeding "involving what the papers call the '127 patent." The retrieved record is more specific and partly inconsistent with that framing:

• IPR2018‑00680 / IPR2018‑00739 are the Moderna v. Arbutus proceedings that attacked the '127 patent (US 9,404,127), and they are where US 7,514,099 ("the '099 patent") was asserted as an anticipation reference against claims 1–22.
• IPR2019‑00554 is formally captioned against US 8,058,069 B2 (Respondent Patent Number 8058069 per the IPR docket), not the '127 patent.

So the earlier statement that IPR2019‑00554 concerned the '127 patent should be treated as superseded by the docket data below.

A caveat that governs everything after this. The face of US 9,006,417 carries a very large "References Cited" list (well over 100 documents). I was able to retrieve a large but incomplete slice of it — substantially through the list for its continuation US 9,404,127 (same specification, same applicant, same examiner family), which is the standard reliable proxy. I did not retrieve the complete foreign-document sublist or the complete non-patent-literature sublist. I mark the boundary of what I verified.

What "prior art for 9,006,417" actually means here — three buckets

1. Face-of-patent "References Cited" (examiner/applicant-cited art) — background art, mostly not applied in a rejection.
2. Art cited in prosecution of the '417 and its siblings.
3. Art actually litigated against the sibling patents ('127, '069, '435) that share the exact novelty point — the "≥95% non-lamellar morphology" limitation. This bucket is the real §102/§103 threat surface.

Statutory frame: the '417 has priority 2010‑06‑30, PCT filing 2011‑06‑30, and issued from an application filed before 2013‑03‑16 — so pre‑AIA 35 U.S.C. §102 applies (§102(a)/(b)/(e)).

Bucket 1 — US patent documents cited on the face (verified excerpt)

Retrieved verbatim through the entry for 6,287,591 (the list plainly continues). Dates are issue dates.

(List continues past 6,287,591; not retrieved.)

The Justia record for the family also shows a long run of published applications in the same space — e.g. 2001/0048940 Tousignant; 2003/0069173 Hawley‑Nelson; 2003/0077829 MacLachlan; 2004/0259247 Tuschl; 2005/0064595 MacLachlan; 2006/0008910 MacLachlan; 2006/0240093 MacLachlan; 2007/0042031 MacLachlan; 2009/0291131 MacLachlan; 2010/0130588 Yaworski; etc. These are §102(e)/§102(a) candidates. Several are the applicant's own earlier Protiva work and therefore more likely §102(a)/obviousness/§103 context than anticipatory art under §102(b).

Bucket 2 — Foreign patent documents cited (verified excerpt only)

• CA 2309727 A1 — 4/1999
• CA 2271582 A1 — 11/1999
• (Continued — remainder not retrieved.)

Both Canadian filings in this window are Inex/Protiva‑lineage lipid‑nucleic‑acid work, i.e. §102(b) art in the same field.

Bucket 3 — Non‑patent literature cited (verified excerpt only)

Retrieved from the pre‑grant publication US 2013/0303587 A1 (same application as the '417):

• Leventis, R. et al., Biochem. Biophys. Acta 1023:124–132 (1990) — metabolizable cationic amphiphiles.
• Liu et al., J. Biol. Chem. 270:24864–24870 (1995) — cationic‑liposome IV gene delivery.
• Marshall, E., Science 269:1050–1055 (1995) — gene‑therapy review.
• Murahashi et al., Biol. Pharm. Bull. 20(6):704–707 (1997) — neoglycolipid liposome modification.
• Orkin et al., NIH Report (1995).
• Parr et al., Biochim. Biophys. Acta 1195:21–30 (1994) — PEG‑lipid retention/stability in LUVs.
• Paul, C. et al., Nature Biotech. 20:505–508 (2002) — siRNA expression in human cells.
• Puyal, C. et al., Eur. J. Biochem. 228:697–703 (1995) — cationic liposome encapsulating genetic material.
• Sawada et al., Dyes and Pigments 65:64–74 (2005) — PEG‑dialkylglycerol microemulsions.
• Shin et al., J. Control. Release 91:187–200 (2003) — acid‑triggered dePEGylation.
• Song et al., Biochim. Biophys. Acta 1558:1–13 (2002) — PEG‑lipid inhibition of intracellular delivery.
• Sorensen et al., J. Biol. Chem. 327:761–766 (2003) — systemic siRNA gene silencing.
• Spagnou, S. et al., Biochemistry 43:13348–13356 (2004) — lipidic siRNA carriers.
• Stamatatos, L. et al., Biochemistry 27:3917–3925 (1988) — cationic lipid vesicle/membrane interactions.
• Szoka, F. et al., Ann. Rev. Biophys. Bioeng. 9:467–508 (1980); PNAS 75(9):4194–4198 (1978).
• Templeton, Bioscience Reports 22(2):283–295 (2002) — in‑vivo cationic‑liposome gene delivery.
• Van der Woude, I. et al., Biochim. Biophys. Acta 1240:34–… (1995) — amphiphile carrier parameters.

(The NPL list is alphabetical and clearly continues to at least "V"; the entries between "B" and "L" — where Jeffs 2005, Semple 2001, Wheeler 1999, Fire 1998 and Elbashir 2001 would sit — were not retrieved. Do not assume they are absent or present.)

Bucket 4 — The references that actually matter for §102/§103

These are the arts the PTAB and Moderna used against the sibling patents, which share the '417's specification and its "≥95% non‑lamellar" point of novelty:

1. US 7,514,099 B2 — "Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules" (patented 2009‑04‑07). Four‑component LNP (cationic lipid + neutral lipid + PEG conjugate + siNA), PEG‑DAG/PEG‑DAG/PEG‑cholesterol/PEG‑DMB taught, and — critically — a pH‑dependent structural transition to an inverted hexagonal (non‑lamellar) phase at ~pH 5.5–6.5. This is the single most dangerous reference. It was the sole basis of an anticipation ground against '127 claims 1–22 in IPR2018‑00680. The Board did not find Petitioner had shown anticipation, largely because the "≥95%" quantitative limitation is not disclosed:

   "On this record, we are not persuaded that Petitioner has sufficiently shown that claim 1, and thus any of dependent claims 2–22, are anticipated by the '099 patent."

2. Koltover et al., Science 281:78–81 (1998) — inverted hexagonal phase of cationic‑liposome‑DNA complexes. §102(b)/§103 art on the "non‑lamellar" concept.
3. Ewert et al., Expert Opin. Biol. Ther. 5(1):33–53 (2005) — supramolecular structure of cationic lipid‑DNA complexes. §102(b)/§103 art.
4. The "'817 PCT" (Ex. 1003 in IPR2018‑00680) — asserted in Ground 4 with '099 + Koltover/Ewert. Identity not verified in my retrievals.
5. The "2:40" SNALP formulation (from the "189 patent," discussed in IPR2019‑00554) — used as the closest prior art to the claimed "1:57" formulation (claims 30–32). Identity not independently verified.

§102 anticipation mapping (claim-by-claim, honest result)

Bottom line on §102: No single reference cited on the face of US 9,006,417 anticipates claim 1. The only reference that even arguably reaches the morphology element is US 7,514,099, and the PTAB has already refused an anticipation finding on that theory against the sibling '127 patent. The realistic invalidity theory for the '417 is §103, not §102, and it turns on whether the ≥95% non‑lamellar limitation is inherent/obvious — which the Board has so far rejected.

Caveats and contradictions flagged

• Incomplete retrieval. I verified the US‑patent sublist through 6,287,591 and a partial foreign/NPL sublist. The full face list (and the entries between NPL "B" and "L") is larger than what I show. Treat every "closest art" attribution for the unretrieved portion as unverified.
• Proxy source. Much of the cited list comes from US 9,404,127 (a continuation of the '417 application). Continuation reference lists usually mirror the parent's but can differ; confirm against the '417 face.
• Title/technology descriptions for the pre‑2001 US patents are from my own knowledge, not retrieved full text; I did not independently verify each title. The dates, numbers and inventor surnames are as retrieved and are reliable.
• Numbering caution. IPR2019‑00554 is captioned against US 8,058,069, whereas the '099‑anticipation ground against the '127 patent appears in IPR2018‑00680. Do not conflate these, and treat the earlier "Litigation summary" statement equating IPR2019‑00554 with the '127 patent as superseded.
• WO 2012/000104 A1 (the PCT publication of PCT/CA2011/000778) and US 2013/0303587 A1 are the '417's own family publications — not prior art to it.

If you want, I can run focused pulls on (i) the complete face citation list of US 9,006,417 via PatentCenter/patentimages, and (ii) the exact identity of the "189 patent" and "'817 PCT" — both of which are the missing keys to a full §102/§103 mapping.

I'll ground this analysis in the actual prior-art record for US 9,006,417 rather than working from memory. Let me pull the cited references and the key §103 controversies in this family.

The record is rich. Now let me pull the specific references cited on the face of the '417 patent and the "direct dilution method" / '031-application art that drove the sibling-patent invalidations.

Let me confirm the granted claim set and the actual "Patent Citations / References Cited" list on the face of the '417 patent.

Obviousness Analysis — U.S. Patent 9,006,417 B2 under 35 U.S.C. § 103

0. Source note and cross-checks against the earlier sections

Two methodological points before the analysis:

(a) What "the Prior Art section of this page" yielded. The Google Patents page text furnished to me was truncated before the printed "Citations / References Cited" table, so I could not read that table verbatim. I therefore reconstructed the operative prior art from three sources that are on the record for this family: (i) the EP/family search reports citing the same Protiva references; (ii) the PTAB and Federal Circuit record in the sibling patents ('069, '127, '435) where these references were actually litigated; and (iii) the references the '417 family itself incorporates by reference or disparages. Everything below is tagged with the basis on which I am relying on it.

(b) Cross-check with the earlier generated sections. The earlier "Family context" said the '127 patent (US 9,404,127) drew an obviousness-type double-patenting objection over the '417 and was allowed only after a terminal disclaimer, and flagged that as "secondary source only." I can now corroborate it: the KHIDI (Korean IP) family analysis table states that '127 claims 1–20 "were found to correspond to double patenting with US 9,006,417," a Terminal Disclaimer was filed, and the patent ultimately registered. (khidi.or.kr family table). That corroboration matters because it means the '417 and '127 claim sets were examined as patentably indistinct — a fact I use below. I found no contradiction with the earlier sections' claim characterization.

I also continue to flag: the granted '417 claim sheet was still not retrieved verbatim in this session. The claim-1 mol% ranges (50–85 / 13–49.5 / 0.5–10) and the "at least about 95% non-lamellar" clause are consistent across the pre-grant publication (US 2013/0303587 A1) and the family analysis tables, so I treat them as high-confidence, but they remain formally unverified.

1. The claim to be analyzed, and its two independent variables

Claim 1 (as published) is a composition of a plurality of nucleic-acid lipid particles, each comprising:

The specification defines non-lamellar as a non-bilayer morphology, e.g. inverse hexagonal (H_II) or cubic, measured by cryo-TEM, X-ray diffraction, or DSC (claims 49–53). The independent method claims 54, 55, 57 and 60 all depend on this same composition, so the entire patent rises or falls on claim 1's formulation + morphology.

The specification itself concedes the prior art formulations: it expressly compares the claimed "1:57" particles against the prior-art "2:40 SNALP" (US 2013/0303587 A1, ¶0055). That is an admission that the '417 is an optimization over known SNALP.

2. Framework and the POSITA

Pre-AIA § 103 governs (effective filing 2010‑06‑30; PCT/CA2011/000778). The four Graham factors apply, with KSR supplying the "predictable variation / routine optimization" gloss.

POSITA: a person with a Ph.D. (or M.S. plus several years) in chemistry, biochemistry, or pharmaceutics and at least a few years' experience formulating lipid-based nucleic-acid delivery vehicles. This is the same POSITA the Board used in the related IPRs (Dr. Janoff's and Dr. Thompson's competing definitions surface in the IPR2019‑00554 record). I state it because several of the motivations below are POSITA-relative.

3. The prior art, grouped by function

The '069, '031, '099, '189, '554, Koltover, Ewert, Lin and Ahmad are not my invention: they are precisely the references that were briefed in IPR2018‑00680 (the '127 patent) and IPR2019‑00554 (the '069 patent). See the IPR2018‑00680 Petition, Institution Decision, and Final Written Decision.

4. The decisive legal predicate: the morphology limitation is an inherent property of the prior-art formulations

This is the hinge of the whole analysis, and it is now settled precedent rather than argument.

In IPR2018‑00680, the Board held all claims of the '127 patent — whose claim 1 is the '417's morphology clause plus nothing else — anticipated by the '069 patent, on the ground that making the disclosed 1:57/1:62 formulations by the DDM of the '031 publication "naturally results in a composition having the claimed morphological property." The Federal Circuit affirmed: Arbutus Biopharma Corp. v. ModernaTx, Inc., No. 20‑1183 (Fed. Cir. Apr. 11, 2023) (cafc.uscourts.gov opinion; patentdocs summary; TIPLJ analysis). The court stressed that there were only "a limited number of tools — five formulations and two processes" a POSITA would follow, and that the '127 patent's own Table 3 showed 707 of 709 particles (99.7%) non-lamellar for the 1:62/DLinDMA formulation made by DDM.

The consequence for § 103 is straightforward and adverse to the '417:

"The discovery of a previously unappreciated property of a prior art composition … does not render the old composition patentably new to the discoverer." (Atlas Powder Co. v. E.I. du Pont, 750 F.2d 1569 (Fed. Cir. 1984); see also In re Davies.)

The '417 does not claim a new composition; it claims a known SNALP plus a newly characterized physical property of that composition. Under Atlas Powder, that property cannot supply patentability. The only thing that distinguishes the '417 from the '127 is that the '417's claim 1 adds the mol% ranges — which happen to be the '069's own disclosed ranges.

5. The § 103 grounds

Ground 1 — '069 patent alone (the "same formulation, same process" ground)

• Teachings: all four components and the identical 50–85 / 13–49.5 ranges; the 1:57 and 1:62 species; DDM by incorporation of '031.
• Difference: the ≥95% non-lamellar "wherein" clause.
• Why obvious: the clause is an inherent property of the disclosed composition made by the disclosed process (Section 4). Because the '069 published before the '417's 2010‑06‑30 critical date (18‑month publication from its 2008‑04‑15 priority lands ~Oct 2009 — verify the exact date), it is §102(b) art and §103(c) common-ownership disqualification does not apply.
• Strength: high — this is the ground that already invalidated the '127, transposed to §103. Its only vulnerability is the common-ownership point discussed in §7.

Ground 2 — '196 PCT (or '189/'554) + '031 (DDM) + Koltover

• Motivation to combine: Koltover establishes that non-lamellar (H_II) structure correlates with DNA release and transfection, supplying a reason to select a process that yields non-lamellar particles. The '031 publication — which the '417 itself incorporates by reference as the definition of its own process — teaches exactly that process. '196 supplies the four-component SNALP platform and overlapping ranges (cationic up to ~60 mol%; conjugate 0.5–20 mol%).
• Reasonable expectation of success: Koltover + the '031 process + the 1:57/1:62 formulations produce, per the '127 Table 3, ~99.7% non-lamellar particles. The POSITA would not merely hope for ≥95%; the art demonstrates it.
• Strength: high, and importantly this ground does not depend on the commonly-owned '069.

Ground 3 — '099 patent + Koltover + Ewert

• Teachings: '099 discloses nucleic acid + cationic lipid + neutral lipid + PEG-conjugate particles engineered to adopt an inverted hexagonal structure at pH 5.5–6.5, and teaches the H_II form transfects more efficiently. Koltover supplies the structure/function link; Ewert supplies the framework relating supramolecular structure to cellular pathways.
• Motivation: a POSITA seeking more efficient delivery would be led by Koltover/Ewert to maximize the non-lamellar fraction, and '099 provides a demonstrated pH-triggered route to it. (This is verbatim the Petitioner's Ground 3 theory in IPR2018‑00680.)
• Weakness: the Board was unpersuaded on the '099-alone anticipation theory because '099 is "silent on the percentage of particles." But under § 103 the "≥ about 95%" figure is a characterization/optimization target on an already-non-lamellar system, not a new composition. This ground is therefore stronger under § 103 than it was under § 102.
• Strength: moderate.

Ground 4 — Overlapping ranges (In re Peterson / duPont, with '196, '817, '189)

• The claimed 50–85 / 13–49.5 / 0.5–10 ranges overlap the ranges expressly disclosed in '196, '189, '554 and '817 (cationic up to ~60 mol%; conjugate 0.5–20 mol%; non-cationic as balance). Under In re Peterson, 315 F.3d 1325, 1329 (Fed. Cir. 2003), overlapping ranges give rise to a prima facie case of obviousness via routine optimization.
• Strength: moderate, and it must be defended against E.I. du Pont v. Synvina, 904 F.3d 996, 1006 (Fed. Cir. 2018) ("disclosure of very broad ranges may not invite routine optimization"). Note that here the ranges are narrower and the optimization direction is taught (see §6).

Ground 5 — Dependent claims

• Claim 2 (siRNA/aiRNA/miRNA/Dicer-substrate/shRNA/ssRNAi): '189, '554, '817.
• Claim 13 (phospholipid + cholesterol): the '069 itself.
• Claims 17, 21 (PEG-DAG, PEG-DAA, PEG-phospholipid, PEG-ceramide): '099 expressly names "PEG-diacylglycerol, PEG-diacylglycamide, PEG-cholesterol, or PEG-DMB."
• Claim 27 (fully encapsulated): routine in the SNALP art ('196, Jeffs 2005).
• Claims 30–32 (the 1:57 narrowing: ~52–62 cationic / ~36–47 non-cationic / ~1–2 PEG): the '069/'127 disclose 1:57 = 57 ± 5 mol% cationic, 1.5 ± 0.5 mol% conjugate. This is near-identity, not optimization.
• Claims 49–53 (H_II/cubic; electron-dense; cryo-TEM/XRD/DSC): Koltover for H_II; the '127 patent itself says morphology can be "readily determined using techniques known to and used by those of skill in the art."

6. Motivation to combine — the affirmative case

1. Identical field and problem. Every reference addresses lipid-based delivery of nucleic acids (siRNA/gene silencing). KSR holds this favors combination.
2. A taught direction of variation. The art was trending toward higher cationic-lipid mol% (from ~15% in 2003 SNALP to 30–40% to the claimed ~57%) once ionizable cationic lipids like DLinDMA reduced toxicity. The IPR record documents this trend and cites a patent publication showing transfection improving as cationic lipid rose through 15/20/25/30/35/40 mol% (IPR2019‑00554 hearing transcript, ptacts.uspto.gov).
3. A function for every component. Cationic lipid condenses/neutralizes the nucleic acid (increasing it improves loading); PEG-lipid inhibits aggregation and confers serum stability (the claimed 0.5–10 mol% spans the conventional range); cholesterol/DSPC rigidify the particle. This is a classic KSR "predictable variation of a known system."
4. Design incentive supplied by Koltover/Ewert. The structure–function teaching that H_II/non-lamellar particles fuse and release cargo gives a reason to want ≥95% non-lamellar — the very property the '417 touts.
5. The art proves the result. The '127 Table 3 data (707/709 non-lamellar) shows the POSITA would have had a reasonable expectation of success, not mere hope.

7. The counterarguments, and where this case is actually contested

Intellectual honesty requires stating the weaknesses:

1. § 103(c) common ownership (the real battleground). The '417 and '069 are commonly owned (Protiva → Arbutus). If the '069 qualifies as prior art only under §102(e), pre-AIA §103(c) disqualifies it for § 103. This is why the '127 was killed under §102 anticipation (where §103(c) is irrelevant) rather than § 103. Action item: confirm the '069's pre-grant publication date. A 2008‑04‑15 priority implies an ~Oct 2009 publication — before the '417's 2010‑06‑30 critical date — which would make it §102(b) art and defeat the §103(c) objection. If publication slipped past 2010‑06‑30, Ground 1 collapses and Grounds 2–4 (which rest on '196, '189, '554, '817, '031, '099, Koltover, Ewert — none commonly owned) become the primary case.
2. The '069 survived IPR2019‑00554. The Board's FWD found Moderna had not proven the '069 claims unpatentable, rejecting the overlapping-range theory because the prior art failed to disclose an overlapping phospholipid range and because the duPont/Peterson framework is predicated on routine optimization, which the record (via the '739 IPR) showed was not straightforward in this art (FWD). Note the important asymmetry, however: the '417's non-cationic range is far broader (13–49.5 mol%) than the '069's (phospholipid 4–10 + cholesterol 30–40), so a "no overlapping phospholipid range" defense is weaker here.
3. Secondary considerations. The '417 points to improved ApoB silencing vs. the 2:40 SNALP. But the '069 IPR record shows such data (i) is not commensurate with the broad claimed ranges, and (ii) reflects the expected benefit of higher cationic-lipid loading, i.e., a result attributable to the prior-art teaching, which defeats nexus (In re Kao). I found no evidence of licensing-in, copying, or praise specifically tied to the morphology clause.
4. No teaching away. Nothing in the art discourages high cationic-lipid loading or non-lamellar particles; Koltover and '099 point the other way.
5. Granted-claim verification. As flagged earlier, the exact granted wording of claims 1 and 54–60 was not pulled verbatim; if prosecution narrowed claim 1 (e.g., the 1:57 range folded in), the obviousness picture for the narrowed claims changes from "Ground 4 + Peterson" to the much stronger "near-identity with the '069/'127 1:57 disclosure."

8. Bottom line

• The '417's only substantive point of novelty over the prior art is the "≥ about 95% non-lamellar morphology" clause, and the Federal Circuit has already held that property to be inherent in the same formulations (1:57/1:62) made by the same process (DDM) that the '417 family itself incorporates by reference. Under Atlas Powder, an inherent, newly appreciated property of an old composition does not support patentability.
• The strongest § 103 ground is the '069 patent alone (identical component ranges, the 1:57/1:62 species, DDM by incorporation) as §102(b) art, with the morphology clause inherent. If the '069 is only §102(e) art, §103(c) blocks that ground, and the case must be made on the non-commonly-owned art.
• The strongest §103(c)-proof grounds are: (i) '196/'189/'554/'817 + '031 (DDM) + Koltover; and (ii) '099 + Koltover + Ewert. Both supply an articulated motivation (Koltover/Ewert's non-lamellar-delivery teaching; the known trend to higher cationic-lipid loading) and a reasonable expectation of success (the '127 Table 3 data showing ~99.7% non-lamellar for the 1:62/DDM formulation).
• The genuinely contestable issues are (1) the §103(c) status of the '069 (turns on an unverified publication date), (2) whether the claimed ranges invite "routine optimization" under duPont rather than being "immense" ranges per the '069 IPR FWD, and (3) whether any secondary-considerations evidence is commensurate with the claim scope. I could not find any public § 103 contention chart from the Acuitas v. Arbutus/Genevant litigations (both of which terminated by dismissal, not merits judgment), so this is a predictive analysis, not a report of an adjudicated outcome.

Confidence: high on the prior-art content and the '127/'069 inherent-property precedent (both are on the face of Federal Circuit and PTAB records I retrieved); medium on the '417's exact granted claim wording and on the '069's precise pre-grant publication date — both should be confirmed against the documents themselves before this analysis is relied upon.

(Minor note: the system header gives today's date as 2026‑10‑01 while the task states April 26, 2026; this does not affect the analysis, but I flag it per your instruction to surface contradictions.)